Patents by Inventor Julien Taillemite

Julien Taillemite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for preparing granules
    Patent number: 11844864
    Abstract: A method for preparing granules. A slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: December 19, 2023
    Assignee: Novartis AG
    Inventors: Markus Krumme, Hans De Waard, Klaus-Peter Moll, Adrian Schmidt, Julien Taillemite
  • METHOD FOR PREPARING GRANULES
    Publication number: 20210069114
    Abstract: A method for preparing granules a slurry containing solid API powder particles dispersed in a liquid is prepared. The slurry is fed to a granulator and mixed with a dry base powder within the granulator in order to produce a slurry/base powder mixture. The slurry/base powder mixture produced within the granulator is dried in order to obtain granules containing the solid API particles and the base powder.
    Type: Application
    Filed: August 30, 2018
    Publication date: March 11, 2021
    Inventors: Markus KRUMME, Hans DE WAARD, Klaus-Peter MOLL, Adrian ACHMIDT, Julien TAILLEMITE
  • Pharmaceutical compositions, dosage forms and new forms of the compound of formula (I), and methods of use thereof
    Patent number: 8987285
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 24, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister
  • Pharmaceutical composition containing coated, floating particles
    Patent number: 8927028
    Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias
  • PHARMACEUTICAL COMPOSITIONS, DOSAGE FORMS AND NEW FORMS OF THE COMPOUND OF MULA (I), AND METHODS OF USE THEREOF
    Publication number: 20130252979
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral for mulation of this novel crystalline form, its preparation and use thereof.
    Type: Application
    Filed: December 5, 2011
    Publication date: September 26, 2013
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister
  • GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS
    Publication number: 20100209480
    Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.
    Type: Application
    Filed: September 24, 2008
    Publication date: August 19, 2010
    Inventors: Ralf Altenburger, Maggy B. Saunier, Nicole Bargenda, Michael A. Bock, Sabine Adler, Bruno Buss, Catherine Curdy, Indrajit Ghosh, Stefan Hirsch, Patrice F. Keller, Charu Kochhar, Shoufeng Li, Nicoletta Loggia, Amol S. Matharu, Julien Taillemite, Wei-Qin Tong, Sudha Vippagunta, Hong Wen, Marie-Christine Wolf, Jay P. Lakshman, James Kowalski
  • Pharmaceutical Composition Containing Coated, Floating Particles
    Publication number: 20080317841
    Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.
    Type: Application
    Filed: December 15, 2005
    Publication date: December 25, 2008
    Inventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias